Education
About Us
Working with TipRanks
Follow Us
Tscan Therapeutics, Inc. (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
$1.17
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.17
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.88 - $2.67
Previous CloseN/A
Volume150.47K
Average Volume (3M)616.71K
Market Cap
$68.10M
Enterprise Value$147.47M
Total Cash (Recent Filing)$184.45M
Total Debt (Recent Filing)$95.62M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Mar 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume487,998
30 Day Avg. Volume616,709
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.41
Price to Sales (P/S)120.90
P/FCF Ratio-2.97
Enterprise Value/Market Cap2.17
Enterprise Value/Revenue6.74
Enterprise Value/Gross Profit7.84
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$5.50Price Target Upside370.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$9.82M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyUpdated ALLOHA Phase 1 results show a substantially lower relapse rate and favorable relapse-free and overall survival for TSC-101 versus control, supporting meaningful clinical benefit and helping to de-risk the pivotal program.
Manufacturing InnovationA new 12-day commercial-ready manufacturing process shortens ex vivo expansion, increases cell yield sufficient for higher dosing and potential retreatment, and may reduce cost of goods, improving commercial feasibility.
Regulatory ProgressAgreement with the FDA on pivotal trial design for TSC-101 provides regulatory clarity through an active-control approach and creates a clearer path toward potential registration.
Bears Say
Financial Runway RiskHigh annualized cash burn and a limited cash runway increase the likelihood of future financing needs, which could dilute existing shareholders if clinical timelines slip.
Program Deprioritization And Workforce ImpactPause of the solid tumor PLEXI-T study, discontinuation of solid-tumor development, and a roughly 30% workforce reduction reduce near-term clinical news flow and have prompted negative investor reaction.
Regulatory DelayAn FDA request for a small manufacturing lead-in and fixed-dose assessment adds an operational requirement that delays pivotal study initiation and extends time to registrational data.
TScan Therapeutics News
TCRX FAQ
What was Tscan Therapeutics, Inc.’s price range in the past 12 months?
Tscan Therapeutics, Inc. lowest stock price was $0.88 and its highest was $2.67 in the past 12 months.
What is Tscan Therapeutics, Inc.’s market cap?
Tscan Therapeutics, Inc.’s market cap is $68.10M.
When is Tscan Therapeutics, Inc.’s upcoming earnings report date?
Tscan Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 54 days.
How were Tscan Therapeutics, Inc.’s earnings last quarter?
Tscan Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is Tscan Therapeutics, Inc. overvalued?
According to Wall Street analysts Tscan Therapeutics, Inc.’s price is currently Undervalued.
Does Tscan Therapeutics, Inc. pay dividends?
Tscan Therapeutics, Inc. does not currently pay dividends.
What is Tscan Therapeutics, Inc.’s EPS estimate?
Tscan Therapeutics, Inc.’s EPS estimate is -0.27.
How many shares outstanding does Tscan Therapeutics, Inc. have?
Tscan Therapeutics, Inc. has 52,471,405 shares outstanding.
What happened to Tscan Therapeutics, Inc.’s price movement after its last earnings report?
Tscan Therapeutics, Inc. reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of Tscan Therapeutics, Inc.?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (370.09% Upside)
$5.50 (370.09% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $144.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.37%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-24.65%
Trailing 12-Months
Company Description
Tscan Therapeutics, Inc.
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$5.50
▲(370.09% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
20.20% Insiders
6.20% Mutual Funds
43.85% Other Institutional Investors
24.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---